Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.), Novartis AG and AbbVie Inc. are Dominating the Europe Palmoplantar Pustulosis Market in 2019

Europe Palmoplantar Pustulosis (PPP) Market is expected to grow with the CAGR of 4.5% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/europe-palmoplantar-pustulosis-market

Palmoplantar pustulosis (PPP) market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in Europe palmoplantar pustulosis (PPP) market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance

  • In July 2020, Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.) received FDA approval for TREMFYA (guselkumab) in order to treat inflammatory disease psoriatic arthritis by targeting the IL-23 immune cells, which has also been reported to cause palmoplantar pustulosis. This approval thus paved the way for the company to attain a lucrative growth in palmoplantar pustulosis market.

Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.) is the dominating player in the market. The other key players existing in the market includes Novartis AG, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., AbbVie Inc., Bristol-Myers Squibb Company, Perrigo Company plc, F. Hoffmann-La Roche Ltd, WOCKHARDT, Teligent, Bausch Health Companies Inc., Mylan N.V. , The Daavlin Company, GlaxoSmithKline plc., Amneal Pharmaceuticals LLC., among Xiromed others.

Europe Palmoplantar Pustulosis Market

Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.)

Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.) was incorporated in 1961 and is headquartered in New Jersey, U.S. The company is focused on providing innovative solutions for most of the devastating disease in various therapeutic areas involving cardiovascular, immunology among others. The company business segment is pharmaceuticals, consumer, medical Devices. The company is providing products under Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, Other. The market focus products lie under Immunology. The company is engaged in continuous development of Palmoplantar pustulosis treatment.

  • In December 2018, Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.) submitted supplemental biologics application for STELARA (ustekinumab). This drug has been proved to target and inhibits the IL-23 cytokines which activates during the palmoplantar pustulosis, this application submission proved to be the important initiative take by the company to evolve itself in palmoplantar pustulosis market.

The company has wide presence across the America, Europe, Middle East & Africa, Asia-Pacific. Janssen-Cilag A/S (Denmark), Janssen Pharmaceutica (Pty.) Ltd. (South Africa), Johnson & Johnson del Perú SA (Peru), Janssen-Cilag Farmacêutica Ltda. (Brazil) and Janssen Pharmaceuticals, Inc. (U.S) among others.

Novartis AG:

Novartis AG was founded in 1996. The company headquarter is in Basel, Switzerland. The company focuses on innovating new solutions for various health care challenges. The company business segment is innovative medicines, Sandoz. The company is engaged in providing products in categories such as cancer, cardiovascular, renal & metabolism, immunology & dermatology, ophthalmology, neuroscience, respiratory, immunology & dermatology the market focused category.

The company has wide presence across Americas, Asia-Pacific, Europe/Middle East/Africa. The company has various subsidiary companies such as Novartis Argentina S.A., Buenos Aires (Argentina), Novartis Australia Pty Ltd, Macquarie Park, NSW (Australia), Novartis Austria GmbH, Vienna(Austria), Novartis Pharma NV, Vilvoorde (Belgium) and Sandoz (China) Pharmaceutical (China) among others. The company has initiated many strategic initiatives to expand its market.

For instance-

  • In November 2017, Novartis AG obtained long-term efficacy data for its product Cosentyx for treatment of palmoplantar psoriasis a disease that leads to the formation of pustules on hand and feet. This data obtained suggested that 59% and 53% of palmoplantar psoriasis patients who have been obtained effective result with the Cosentyx and have achieved clear palms. Thus, the data obtained allowed the company to establish its network in the palmoplantar pustulosis market.

The company has wide presence across Americas, Asia-Pacific, Europe/Middle East/Africa. The company also has various subsidiary companies such as Novartis Argentina S.A., Buenos Aires(Argentina), Novartis Australia Pty Ltd, Macquarie Park, NSW(Australia), Novartis Austria GmbH, Vienna(Austria), Novartis Pharma NV, Vilvoorde (Belgium) and Sandoz (China) Pharmaceutical (China) among others.

AbbVie Inc.

AbbVie Inc. headquartered in North Chicago, Illinois, U.S.A., was incorporated in 2013. The company is a research-driven biopharmaceutical company having a great focus on treating diseases in order to make a remarkable impact on people's lives. The company has multiple business segments such as Immunology, Hematologic Oncology, HCV, Other Key Products. In which the market focused segment is immunology. The company is providing products under AndroGel (testosterone gel), CREON (pancrelipase) Delayed-Release Capsules, Depakote (divalproex sodium) tablets, GENGRAF Capsules (cyclosporine capsules, USP), GENGRAF Oral Solution (cyclosporine oral solution, USP), DUOPA (carbidopa/levodopa enteral suspension), HUMIRA (adalimumab), KALETRA (lopinavir/ritonavir) Tablets and KALETRA (lopinavir/ritonavir) Oral Solution, LUPRON DEPOT (leuprolide acetate for depot suspension) URO, MAVYRET (glecaprevir/pibrentasvir), NORVIR Tablets (ritonavir tablets/oral solution), ORILISSA (elagolix) tablets, TARKA (trandolapril/verapamil HCI ER) among others. The market focus products lie under immunology category. The company is engaged in continuous development palmoplantar pustulosis treatment.

For instance:

  • In May 2019, AbbVie Inc. resolved the litigation associated with Boehringer Ingelheim (BI) for HUMIRA. According to this resolution agreement, AbbVie Inc. will grant Boehringer Ingelheim (BI) a nonexclusive license for HUMIRA in the United States, which allows the company to expand its market in the U.S. This patent resolution thus allowed the company to fix a strong foot in the market.

 The company has wide presence across Africa, Asia-Pacific, Europe, Latin America, Middle East, North America, South America. The company also has various subsidiary companies such as Knoll Pharmaceutical Company (New Jersey), AbbVie S.A.(Argentina), AbbVie Pty Ltd (Australia), AbbVie SA(Belgium) and AbbVie SAS(Colombia) among others.